Harmony Biosciences Holdings Inc (NAS:HRMY)

$ 34.2 -0.52 (-1.5%) Market Cap: 1.95 Bil Enterprise Value: 1.75 Bil PE Ratio: 16.21 PB Ratio: 3.27 GF Score: 65/100

Q3 2024 Harmony Biosciences Holdings Inc Earnings Call Transcript
Oct 29, 2024

$41.49 (+16.06%)

Earnings
Q2 2024 Harmony Biosciences Holdings Inc Earnings Call Transcript
Aug 06, 2024

$32.83 (+6.18%)

Earnings
Q1 2024 Harmony Biosciences Holdings Inc Earnings Call Transcript
Apr 30, 2024

$30.91 (+5.68%)

Earnings
Q4 2023 Harmony Biosciences Holdings Inc Earnings Call Transcript
Feb 22, 2024

$31.45 (-4.70%)

Earnings
Harmony Biosciences Holdings Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2024
Q3 2023 Harmony Biosciences Holdings Inc Earnings Call Transcript
Oct 31, 2023

$23.54 (+19.43%)

Earnings
Harmony Biosciences Holdings Inc To Acquire Zynerba Pharmaceuticals Inc- M&A Call Transcript
Aug 14, 2023
Q2 2023 Harmony Biosciences Holdings Inc Earnings Call Transcript
Aug 01, 2023

$33.99 (-3.90%)

Earnings
Harmony Biosciences Holdings Inc at Goldman Sachs Healthcare Conference Transcript
Jun 13, 2023
Q1 2023 Harmony Biosciences Holdings Inc Earnings Call Transcript
May 02, 2023

$33.55 (+2.41%)

Earnings
Q4 2022 Harmony Biosciences Holdings Inc Earnings Call Transcript
Feb 21, 2023

$43.81 (-11.08%)

Earnings
Harmony Biosciences Holdings Inc at JPMorgan Healthcare Conference Transcript
Jan 12, 2023
Q3 2022 Harmony Biosciences Holdings Inc Earnings Call Transcript
Nov 01, 2022

$59.26 (+13.96%)

Earnings
Q2 2022 Harmony Biosciences Holdings Inc Earnings Call Transcript
Aug 02, 2022

$55.42 (+12.57%)

Earnings
Q1 2022 Harmony Biosciences Holdings Inc Earnings Call Transcript
May 03, 2022

$37.18 (-17.56%)

Earnings
Harmony Biosciences Holdings Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 11, 2022
Harmony Biosciences Holdings Inc at Needham Neuroscience Forum (Virtual) Transcript
Mar 16, 2022
Q4 2021 Harmony Biosciences Holdings Inc Earnings Call Transcript
Feb 28, 2022

$39.96 (+5.35%)

Earnings
Harmony Biosciences Holdings Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2022
Q3 2021 Harmony Biosciences Holdings Inc Earnings Call Transcript
Nov 09, 2021

$42.18 (-0.94%)

Earnings
Q2 2021 Harmony Biosciences Holdings Inc Earnings Call Transcript
Aug 10, 2021

$30.16 (+12.66%)

Earnings
Harmony Biosciences Holdings Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript
Jun 21, 2021
Harmony Biosciences Holdings Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2021
Harmony Biosciences Holdings Inc at Jefferies Healthcare Conference (Virtual) Transcript
Jun 02, 2021
Q1 2021 Harmony Biosciences Holdings Inc Earnings Call Transcript
May 11, 2021

$25.96 (-3.13%)

Earnings
Q4 2020 Harmony Biosciences Holdings Inc Earnings Call Transcript
Mar 25, 2021

$29.75 (+3.48%)

Earnings
Harmony Biosciences Holdings Inc at Piper Sandler Healthcare Conference (Virtual)- Pre-recorded Firside Chat Transcript
Nov 30, 2020
Q3 2020 Harmony Biosciences Holdings Inc Earnings Call Transcript
Nov 12, 2020

$43.94 (-7.44%)

Earnings

Harmony Biosciences Holdings Inc To Acquire Zynerba Pharmaceuticals Inc- M&A Call Transcript

Aug 14, 2023 / 12:30PM GMT

Release Date Price: $32.4 (+1.54%)

Transcript

Operator

Good morning. My name is Ashley, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Harmony Biosciences proposed acquisition of Zynerba Pharmaceutical Conference Call. (Operator Instructions) Please be advised, today's conference call is being recorded. (Operator Instructions).

I will now turn the call over to Luis Sanay, Head of Investor Relations. Please go ahead.

Luis Sanay

Harmony Biosciences Holdings, Inc. - Head of IR

Good morning, everyone. Welcome to Harmony Biosciences conference call to discuss the proposed acquisition of Zynerba Pharmaceuticals. Our speakers on today's call are Dr. Jeffrey Dayno, President and CEO; and Sandip Kapadia, Chief Financial Officer. Following our brief prepared remarks, Jeffrey Dierks Chief Commercial Officer; and Dr. Kumar Budur, Chief Medical Officer, will also be available for the Q&A portion of the call.

As a reminder, we will be making forward-looking statements today, which are based on our current expectations and beliefs. These statements are

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.